Testing bacterial DNA in belly fluid to diagnose SBP in cirrhosis
Part of Infections clinical trials.
This study tests a new way to detect bacteria in the fluid in your belly (ascites) to see if it can quickly diagnose a serious infection called spontaneous bacterial peritonitis (SBP) in people with cirrhosis. If you have cirrhosis and ascites, this trial may help improve how fast infections are found.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with cirrhosis, a condition where the liver is scarred.
- You have fluid buildup in your belly, called ascites, which is related to your liver disease.
- You do not have an active infection in another part of your body, like a urinary tract or lung infection.
- You are not pregnant, do not use intravenous drugs, and do not have HIV.
- You are not currently taking steroids or other medicines that weaken your immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at ways to predict a serious infection in the belly fluid (called spontaneous bacterial peritonitis) that can happen in people with cirrhosis. It aims to find easy markers to catch this infection early and help guide treatment.
This trial tests whether removing infected fluid from the belly early helps people with cirrhosis and an infection called SBP. It may reduce the chance of complications and improve recovery.
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
This study looks at bacterial infections in people with cirrhosis to understand which antibiotics still work. The goal is to improve treatment for future patients with liver disease.
This study looks at how your body uses protein in your muscles when you have cirrhosis (a scarred liver). It uses a special “tracer” method (a substance that can be tracked) and may help researchers better understand muscle loss in people with milder cirrhosis.
This study measures how antibiotic drugs called beta-lactams work in people with cirrhosis (liver damage). Researchers will check antibiotic blood levels to see if standard doses are right for cirrhotic patients or need adjustment.
Hear when a new Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.